Literature DB >> 25832135

Physical capacity in performing daily activities is reduced in scleroderma patients with early lung involvement.

Salvatore Battaglia1, Maria Bellia1, Laura Serafino-Agrusa1, Annarita Giardina2, Maria Messina1, Fabio Cannizzaro3, Massimo Midiri3, Giovanni Triolo2, Nicola Scichilone1.   

Abstract

BACKGROUND AND AIMS: Patients with systemic sclerosis (SSc) often complain reduced capacity at submaximal exercise; conversely, physical capacity in performing daily duties has never been measured in SSc. The aim of this study is to evaluate this performance and its correlates, in patients with SSc compared with healthy controls, in a free-living setting.
METHODS: Twenty-seven outpatients with stable SSc and 11 controls were recruited. Physical activity was assessed by portable multiple sensor device (SenseWear Armband) worn for at least 6 days. Physical activity duration (PAD; in minutes) for non-sedentary activities and physical activity level (PAL = total daily energy/resting energy expenditure) per day were calculated. Nutritional status was estimated by bioelectrical impedance analysis and pulmonary arterial hypertension excluded by echocardiography.
RESULTS: Daily physical activities (243 ± 145 min per day vs 397 ± 142 min, respectively; P = 0.005) and PAL were significantly reduced in SSc compared with controls (1.5 ± 0.4 vs 2 ± 0.7, respectively; P = 0.019). Seventy-four per cent of SSc patients showed PAL < 1.70, whereas only 27% of controls were below this threshold for sedentary life style. Both PAD and PAL positively correlated with DLco. Patients and controls did not differ for spirometric parameters, body mass index, phase angle at bioelectrical impedance analysis, fat mass or fat-free mass indexes. In SSc, exercise capacity during daily activity was reduced compared with controls, and was associated with early evidence of functional decay (decreasing DLco) but not with malnutrition (undernutrition).
CONCLUSIONS: A reduction of daily physical activity is already present even in early stages of lung involvement in SSc, characterized by unaltered spirometry and well-preserved nutritional status.
© 2015 John Wiley & Sons Ltd.

Entities:  

Keywords:  lung function; motion sensors; physical activity; scleroderma

Mesh:

Year:  2015        PMID: 25832135     DOI: 10.1111/crj.12299

Source DB:  PubMed          Journal:  Clin Respir J        ISSN: 1752-6981            Impact factor:   2.570


  4 in total

1.  The need to accurately measure energy intake and expenditure in patients with systemic sclerosis.

Authors:  Michael Hughes; Elizabeth Harrison; Ariane L Herrick; John T McLaughlin; Simon Lal
Journal:  J Scleroderma Relat Disord       Date:  2022-05-30

Review 2.  Exercise as a multi-modal disease-modifying medicine in systemic sclerosis: An introduction by The Global Fellowship on Rehabilitation and Exercise in Systemic Sclerosis (G-FoRSS).

Authors:  Henrik Pettersson; Helene Alexanderson; Janet L Poole; Janos Varga; Malin Regardt; Anne-Marie Russell; Yasser Salam; Kelly Jensen; Jennifer Mansour; Tracy Frech; Carol Feghali-Bostwick; Cecília Varjú; Nancy Baldwin; Matty Heenan; Kim Fligelstone; Monica Holmner; Matthew R Lammi; Mary Beth Scholand; Lee Shapiro; Elizabeth R Volkmann; Lesley Ann Saketkoo
Journal:  Best Pract Res Clin Rheumatol       Date:  2021-07-01       Impact factor: 4.991

3.  The Preventive Role of Physical Activity in Systemic Sclerosis: A Cross-Sectional Study on the Correlation with Clinical Parameters and Disease Progression.

Authors:  Cristina Antinozzi; Elisa Grazioli; Maria De Santis; Francesca Motta; Paolo Sgrò; Federico Mari; Caterina Mauri; Attilio Parisi; Daniela Caporossi; Guglielmo Duranti; Roberta Ceci; Luigi Di Luigi; Ivan Dimauro
Journal:  Int J Environ Res Public Health       Date:  2022-08-18       Impact factor: 4.614

4.  Physical activity in patients with systemic sclerosis.

Authors:  S I E Liem; J M T A Meessen; R Wolterbeek; N Ajmone Marsan; M K Ninaber; T P M Vliet Vlieland; J K de Vries-Bouwstra
Journal:  Rheumatol Int       Date:  2017-11-18       Impact factor: 2.631

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.